Otonomy (OTIC) Earns Daily Coverage Optimism Rating of 0.11

Share on StockTwits

Headlines about Otonomy (NASDAQ:OTIC) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Otonomy earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 48.6805316062806 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

OTIC has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Otonomy from a “sell” rating to a “hold” rating in a report on Monday, June 4th. Zacks Investment Research upgraded shares of Otonomy from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Saturday, April 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $8.95.

Shares of Otonomy remained flat at $$3.50 during midday trading on Friday, according to Marketbeat. 139,044 shares of the stock were exchanged, compared to its average volume of 154,915. The stock has a market capitalization of $107.21 million, a P/E ratio of -1.18 and a beta of 3.03. Otonomy has a 1-year low of $2.80 and a 1-year high of $21.15.

Otonomy (NASDAQ:OTIC) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.06). Otonomy had a negative return on equity of 56.60% and a negative net margin of 6,640.16%. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.30 million. sell-side analysts forecast that Otonomy will post -1.76 earnings per share for the current fiscal year.

About Otonomy

Otonomy, Inc, a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus.

Further Reading: Average Daily Trade Volume Explained

Insider Buying and Selling by Quarter for Otonomy (NASDAQ:OTIC)

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply